Combination of targeted biological agents such as anti-epidermal growth factor receptor (EGFR) with FOLFOX have been reported to enhance the efficacy against EGFR-expressing metastatic colorectal cancer (Giantonio, 2006; Tabernero et al, 2007). Here, EGFR is linked to metastatic colorectal cancer.